Биостатистика, фармакокинетика и клинические исследования.

Домашняя страница
- О сайте
Материалы
- Быстрые команды R Project
- Ссылки
Инструменты
- Рандомизационный список
Блог
Контакты
Профиль
- Войти
- Зарегистрироваться

Long WS Wide: или про то, как выполнить анализ разницы изменений между группами
Частые вопросы: Регистрация и экспертиза по правилам ЕАЭС
Главные ошибки при формировании базы данных в MS Excel
Тест ClinicalTrialUtilities и ReplicateBE на Raspberry Pi 4
Julia:ReplicateBE – release 0.2.0

Галерея

Biologics Electronic Reading Room (eFOIA)
Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2025-09-02 By FDA
Drug Safety Oversight Board
Source: FDA - What's New: Drugs RSS Feed Published on 2025-09-02 By FDA
DG Gel Card 125445, 125449, 125450 - 125457
Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2025-09-02 By FDA
FDA-TRACK: Prescription Drug User Fee Act Meeting Goals Summary
Source: FDA - What's New: Drugs RSS Feed Published on 2025-09-02 By FDA
FDA-TRACK: Prescription Drug User Fee Act Procedural Goals Summary
Source: FDA - What's New: Drugs RSS Feed Published on 2025-09-02 By FDA
FDA-TRACK: Prescription Drug User Fee Act Review Goals Summary
Source: FDA - What's New: Drugs RSS Feed Published on 2025-09-02 By FDA
Obstetrics, Reproductive and Urologic Drugs Advisory Committee (formerly Bone, Reproductive and Urologic Drugs Advisory Committee) Roster
Source: FDA - What's New: Drugs RSS Feed Published on 2025-09-02 By FDA
Over-The-Counter Monograph Drug User Fee Program (OMUFA)
Source: FDA - What's New: Drugs RSS Feed Published on 2025-09-02 By FDA
Meetings, Conferences, & Workshops | Drugs
Source: FDA - What's New: Drugs RSS Feed Published on 2025-09-02 By FDA
Assessing Novel Efficacy Endpoints in Ophthalmologic Rare Disease Drug and Biologics Development - 09/17/2025
Source: FDA - What's New: Drugs RSS Feed Published on 2025-09-02 By FDA
Human medicines European public assessment report (EPAR): Azarga, brinzolamide,timolol, Date of authorisation: 25/11/2008, Revision: 18, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-09-02
Human medicines European public assessment report (EPAR): Nuvaxovid, COVID-19 Vaccine (recombinant, adjuvanted), Date of authorisation: 20/12/2021, Revision: 20, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-09-02
Human medicines European public assessment report (EPAR): Simbrinza, brinzolamide,brimonidine tartrate, Date of authorisation: 18/07/2014, Revision: 12, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-09-02
Human medicines European public assessment report (EPAR): Ebilfumin, oseltamivir, Date of authorisation: 22/05/2014, Revision: 16, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-09-02
Human medicines European public assessment report (EPAR): Caelyx pegylated liposomal, doxorubicin, Date of authorisation: 20/06/1996, Revision: 38, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-09-02

Предыдущие записи

Тема: Scaffold от Danny Cooper.